4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $13.65, for a total value of $22,317.75. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $117,622.05. The trade was a 15.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $14.00, for a total value of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total value of $19,947.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $15.88 on Wednesday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock has a market cap of $877.21 million, a PE ratio of -6.04 and a beta of 2.74. The stock’s fifty day simple moving average is $12.95 and its two-hundred day simple moving average is $10.95. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.96 and a 1-year high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FDMT. Jupiter Topco LLC bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $76,466,000. BlackRock Inc. purchased a new position in shares of 4D Molecular Therapeutics in the second quarter valued at $60,463,000. Janus Henderson Group PLC raised its stake in shares of 4D Molecular Therapeutics by 13.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after purchasing an additional 611,276 shares during the period. Trails Edge Capital Partners LP bought a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $29,631,296. Finally, Bank of America Corp DE purchased a new stake in 4D Molecular Therapeutics during the 2nd quarter worth about $14,905,000. Institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

FDMT has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $28.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.